Chair:
Hwoon-Yong Jung（Asan Medical Center, University of Ulsan College of Medicine, Korea）
Hitoshi Tsugawa（ Transkingdom Signaling Research Unit, Division of Host Defense Mechanism, Tokai University School of Medicine, Japan）
　　
YIA-K1 Efficacy of Culture-Based Tailored Therapy as Primary Treatment of Helicobacter pylori Infection
Jeong Hoon Lee（ Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea）
　
YIA-K2 Regression of follicular gastritis after successful eradication of Helicobacter pylori
Yoo Min Han（ Department of Internal Medicine and Healthcare Research Institute, Seoul National University Hospital Healthcare System Gangnam Center, Seoul, 06236, South Korea / Department of Internal Medicine, Seoul National University College of Medicine, Seoul, 03080, South Korea）
　
YIA-K3 Efficacy of a 10-day tegoprazan-based, non-bismuth-containing quadruple therapy for
first-line Helicobacter pylori eradication, open label, single arm study
Yong Hwan Kwon（ School of Medicine, Kyungpook National University, Daegu, South Korea / Department of Internal
medicine, Kyungpook National University Hospital, Daegu, South Korea）
　
YIA-K4 Incidence of gastric cancer among H. pylori eradicated long-term proton pump
inhibitor users in Korea
Jong Wook Kim（Department of Gastroenterology, Inje University Ilsan Paik Hospital, Korea）
　
YIA-K5 Comparison of first-line bismuth containing 7-day quintet therapy and standard 14-day
triple therapy for Helicobacter pylori Eradication
Young Hoon Chang（ Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea）
　
YIA-J1 DLST positivity rate for H. pylori eradication drugs
Tomohiro Higuchi（First Department of Medicine, Hamamatsu University School of Medicine, Japan）
　
YIA-J2 Role of the stimulation of Porphyromonas gingivals-derived lipopolysaccharide in development of inflammatory gastric carcinogenesis.
Masayoshi Oriuchi（Division of Gastroenterology, Tohoku University, Graduate School of Medicine, Japan）
　
YIA-J3 Intervention study of susceptibility testing based vonoprazan, amoxicillin, clarithromycin, and metronidazole 14 days concomitant therapy as fourth line Helicobacter pylori eradication
Soichiro Sue（ Department of Gastroenterology, Yokohama City University Graduate School of Medicine, Yokohama,
Japan）
　
YIA-J4 The Impact of Mobile Genetic Elements and Toxin-antitoxin system on Helicobacter pylori Adaptability and Antimicrobial Resistance: A Wisdom from Japan-South Korea Whole-Genome Sequence Collection
Ricky Indra Alfaray（ Department of Environmental and Preventive Medicine, Faculty of Medicine, Oita University, Yufu, Oita 879-5593 Japan / Institute of Tropical Disease, Universitas Airlangga, Surabaya, 60115, Indonesia）
　
YIA-J5 Identification of the Helicobacter pylori Genomic Islands in a High Gastric Cancer Region
Batsaikhan Saruuljavkhlan（Department of Environmental and Preventive Medicine, Oita University of Medicine, Yufu, Japan）